Critical infrastructure in biopharma and medical devices plays a vital role in enabling innovation, bolstering research and development, and ensuring the production of novel drugs and products. It ensures scalability, quality control, and regulatory compliance.
By investing in advanced labs, manufacturing facilities, regulatory compliance systems, cybersecurity, and global supply chains, companies can ensure they meet the high standards required to bring safe, effective, and innovative products to market. Moreover, with rapid advances in digital technologies, automation, and collaboration, infrastructure is also evolving to support faster, more efficient R&D and manufacturing processes.
According to Vishal Goel, managing director, RX Propellant, the newly introduced Biotechnology for Economy, Environment, and Employment (BioE3) Policy signals a strategic direction for sustainable biomanufacturing in India, addressing critical global challenges like climate change and diminishing natural resources. The initiative aligns with India’s broader goals of Green Growth, a Net Zero economy, and sustainable development.
